Related Experiment Video
Updated: Jul 22, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type
Meggan R Newland1, Andrew Weinstein, Francisco Kerdel
1Department of Dermatology and Cutaneous Surgery, University of Miami, 1444 NW 9th Avenue, Miami, FL 33136, USA. dermatology.department@hcahealthcare.com
Abstract:
Tumor necrosis factor-alpha (TNF-alpha) is a chemokine secreted by T cells which is thought to play a critical role in the pathophysiology of psoriasis. The monoclonal antibody, infliximab, complexes with TNF-alpha, rendering it inactive. A recent clinical trial has reported the clinical benefit and safety of infliximab in moderate to severe plaque psoriasis. We report a case of rapid response and clinical benefit using infliximab in severe pustular psoriasis of von Zumbusch.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Hypersensitivity Reactions: Cytolytic Reactions
Acute Inflammation I: Inflammatory Response
Hypersensitivity Reactions: Immune-Complex Reactions
